Zions Bancorporation N.A. Has $69,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Zions Bancorporation N.A. lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 285 shares of the medical instruments supplier’s stock after selling 59 shares during the period. Zions Bancorporation N.A.’s holdings in Becton, Dickinson and Company were worth $69,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Ameriprise Financial Inc. raised its position in Becton, Dickinson and Company by 6.4% in the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after purchasing an additional 302,893 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton, Dickinson and Company by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after buying an additional 87,230 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares during the period. Clearbridge Investments LLC boosted its stake in Becton, Dickinson and Company by 3.1% in the 2nd quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock valued at $697,513,000 after buying an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after acquiring an additional 688,296 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.9 %

Shares of BDX opened at $225.15 on Friday. The business’s fifty day moving average price is $236.44 and its two-hundred day moving average price is $235.05. The firm has a market capitalization of $65.08 billion, a price-to-earnings ratio of 38.15, a PEG ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Analyst Ratings Changes

A number of brokerages have issued reports on BDX. Raymond James cut their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.